Search

NCX 950

NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.

Descartes-30

Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. … [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.

AD 337

AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). … The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.

Totrombopag

, thus representing a significant problem in the treatment of cancer patients. … This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding

IDM-2

IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells.

Tozorakimab

Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

ATX-201

ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

Dihydromorphine

A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]

Sulfabenzamide

Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.

SAR-260301